Company / Current Assets
BioXcel Therapeutics, Inc. Current Assets History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$44.7M
FY2025
5-year range
$37.4M / $202.9M
FY2022-FY2025
Trend
+19.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets returned to growth in FY2025 after 2 years of decline, reaching $45M.
Based on SEC 10-K filings.
$45M in FY2025 with a 3-year CAGR of -39.6%.
Declined from $72M to $45M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -39.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -39.6%, indicating a declining trend.
- In FY2025, current assets increased 19.5% year-over-year.
Company context
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $44.7M | +19.5% |
| FY2024 | $37.4M | -48.2% |
| FY2023 | $72.1M | -64.4% |
| FY2022 | $202.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026